
UNAIDS DATA **2022** 190

TIMOR-LESTE TIMOR-LESTE

| EPIDEMIC ESTIMATES | | | |
|--|------------------|------------------|------------------|
| | 2010 | 2015 | 2021 |
| New HIV infections | | | |
| New HIV infections (all ages) | <100 | <200 | <200 |
| | [<100- <200] | [<100- <200] | [<100- <500] |
| New HIV infections (0–14) | | | |
| | [–] | [] | [–] |
| New HIV infections (15-24) | <100 | <100 | <100 |
| | [<100-<100] | [<100- <100] | [<100- <100] |
| New HIV infections (women, 15+) | <100 | <100 | <100 |
| | [<100- <100] | [<100- <100] | [<100- <100] |
| New HIV infections (men, 15+) | <100 | <100 | <100 |
| | [<100- <100] | [<100- <200] | [<100- <200] |
| HIV incidence (all ages) per 1000 population | 0.08 [0.06–0.11] | 0.10 [0.07–0.13] | 0.10 [0.04–0.15] |
| AIDS-related deaths | | | |
| AIDS-related deaths (all ages) | <100 | <100 | <100 |
| | [<100- <100] | [<100- <100] | [<100- <100] |
| AIDS-related deaths (0–14) | | | |
| | [=] | [=] | [–] |
| AIDS-related deaths (women, 15+) | <100 | <100 | <100 |
| | [<100- <100] | [<100- <100] | [<100-<100] |
| AIDS-related deaths (men, 15+) | <100 | <100 | <100 |
| | [<100-<100] | [<100- <100] | [<100- <100] |
| People living with HIV | | | |
| People living with HIV (all ages) | 530 | 890 | 1400 |
| | [<500–980] | [700–1200] | [1000–1800] |
| People living with HIV (0-14) | | | |
| | [–] | [] | [] |
| People living with HIV (women, 15+) | <200 | <500 | <500 |
| | [<200- <500] | [<500- <500] | [<500–530] |
| People living with HIV (men, 15+) | <500 | 590 | 940 |
| | [<500–660] | [<500–800] | [690–1200] |
| HIV prevalence (15–49) | <0.1 [<0.1–0.2] | 0.1 [0.1–0.2] | 0.2 [0.1–0.2] |



^{*} The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 91% or higher (the testing and treatment target for 2025).

| EXPENDITURES | | | | | | | | | |
|-----------------------------|------------------|-----------------|--------------------------|-------------------------------|------------------------------|----------------|--|--|--|
| Financing sources | | | | | | | | | |
| | Domestic private | Domestic public | International: PEPFAR | International: Global Fund | International: all others | Total | | | |
| Last available report: 2009 | | US\$ 21 000 | | US\$ 1 743 620 | US\$ 38 394 | US\$ 1 803 014 | | | |

COUNTRY DATA

HIV TESTING AND TREATMENT CASCADE



| ELIMINATION OF VERTICAL TRANSMISSION | | | | | | |
|---|-----------|-----------|--|--|--|--|
| | 2015 | 2021 | | | | |
| Percentage of pregnant women living with HIV accessing antiretroviral medicines | % [–%] | % [–%] | | | | |
| Final vertical transmission rate including during breastfeeding | % [–%] | % [–%] | | | | |
| Early infant diagnosis | % [–%] | % [–%] | | | | |